Literature DB >> 10351135

Platelet autoantibodies in immune thrombocytopenic purpura.

D S Beardsley1, M Ertem.   

Abstract

In summary, the search for a useful clinical laboratory diagnostic assay for the antiplatelet antibodies has been long and difficult. Measurement of platelet associated IgG (PAIgG) has been disappointing as a way to detect autoantibodies. This is primarily due to the fact that platelets normally contain IgG in their alpha granules in an amount that varies with plasma IgG levels and age of the platelets. Furthermore, the amounts of platelet associated IgG is affected by the presence of circulating immune complexes, platelet activation, and drug dependent antibodies. The newer, platelet antigen capture techniques are promising, but further testing will be needed to confirm their value to the clinician. Methods that allow incubation of patient serum or plasma with intact platelets (MAIPA and immunobead) have greater sensitivity than techniques in which the patient antibody is tested against previously isolated platelet glycoproteins. These assays are currently available in a only a limited number of platelet immunology laboratories. Platelet autoantibodies are directed against a number of glycoprotein antigens on the platelet surface. Most studies have shown that anti GPIIb/IIIa antibodies are the most common, although antibodies against GPIb/IX and other targets are frequently detected. Many patients have multiple antiplatelet antibodies circulating simultaneously. The clinical significance of antibodies with different specificity is under investigation. The precise epitopes on GPIIIa that bind antiplatelet autoantibodies have been studied to a limited extent. Some investigators report that the vast majority of platelet antigens are conformation dependent, being destroyed by treatment with EDTA (separation of GPIIb and GPIIIa) or denaturation with detergents. Others report sequence specific peptide antigens. Further investigation promises to better define the targets for platelet autoantibodies; improved clinical management of patients with ITP is the long term goal of these studies.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10351135     DOI: 10.1016/s0955-3886(98)00037-x

Source DB:  PubMed          Journal:  Transfus Sci        ISSN: 0955-3886


  16 in total

1.  Immunodiagnosis of platelet activation in immune thrombocytopenia through scFv antibodies cognate to activated IIb3 integrins.

Authors:  Preeti Bhoria; Neelam Varma; Pankaj Malhotra; Subhash Varma; Manni Luthra-Guptasarma
Journal:  MAbs       Date:  2015-08-24       Impact factor: 5.857

Review 2.  Helicobacter pylori and immune thrombocytopenic purpura: unsolved questions and controversies.

Authors:  Masataka Kuwana; Yasuo Ikeda
Journal:  Int J Hematol       Date:  2006-11       Impact factor: 2.490

3.  CD34+ gene expression profiling of individual children with very severe aplastic anemia indicates a pathogenic role of integrin receptors and the proapoptotic death ligand TRAIL.

Authors:  Ute Fischer; Christian Ruckert; Bernd Hubner; Olaf Eckermann; Vera Binder; Tamam Bakchoul; Friedhelm R Schuster; Sylvia Merk; Hans-Ulrich Klein; Monika Führer; Martin Dugas; Arndt Borkhardt
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

4.  Acute liver failure occurring immediately following anti-D immune globulin infusion in a patient with chronic hepatitis B infection.

Authors:  Manal F Abdelmalek; Lane B Hellner; Marc Zumberg; Victor W Melgen; Richard Lottenberg
Journal:  Dig Dis Sci       Date:  2007-03-09       Impact factor: 3.199

5.  CD8+ T cells are predominantly protective and required for effective steroid therapy in murine models of immune thrombocytopenia.

Authors:  Li Ma; Elisa Simpson; June Li; Min Xuan; Miao Xu; Laura Baker; Yan Shi; Issaka Yougbaré; Xiaozhong Wang; Guangheng Zhu; Pingguo Chen; Gerald J Prud'homme; Alan H Lazarus; John Freedman; Heyu Ni
Journal:  Blood       Date:  2015-06-02       Impact factor: 22.113

6.  Fc-independent immune thrombocytopenia via mechanomolecular signaling in platelets.

Authors:  M Edward Quach; Matthew A Dragovich; Wenchun Chen; Anum K Syed; Wenpeng Cao; Xin Liang; Wei Deng; Simon F De Meyer; Guangheng Zhu; Jun Peng; Heyu Ni; Carolyn M Bennett; Ming Hou; Jerry Ware; Hans Deckmyn; X Frank Zhang; Renhao Li
Journal:  Blood       Date:  2017-12-04       Impact factor: 22.113

7.  Complement activation on platelets correlates with a decrease in circulating immature platelets in patients with immune thrombocytopenic purpura.

Authors:  Ellinor I B Peerschke; Biree Andemariam; Wei Yin; James B Bussel
Journal:  Br J Haematol       Date:  2009-11-19       Impact factor: 6.998

8.  A novel canine model of immune thrombocytopenia: has immune thrombocytopenia (ITP) gone to the dogs?

Authors:  Dana N LeVine; Adam J Birkenheuer; Marjory B Brooks; Shila K Nordone; Dwight A Bellinger; Sam L Jones; Thomas H Fischer; Stephen E Oglesbee; Kahlina Frey; Nicole S Brinson; Allison P Peters; Henry S Marr; Alison Motsinger-Reif; Sif Gudbrandsdottir; James B Bussel; Nigel S Key
Journal:  Br J Haematol       Date:  2014-07-08       Impact factor: 6.998

9.  Complement activation in patients with immune thrombocytopenic purpura according to phases of disease course.

Authors:  R Castelli; G Lambertenghi Delilliers; A Gidaro; M Cicardi; L Bergamaschini
Journal:  Clin Exp Immunol       Date:  2020-07-06       Impact factor: 4.330

10.  Crosstalk between Platelets and the Immune System: Old Systems with New Discoveries.

Authors:  Conglei Li; June Li; Yan Li; Sean Lang; Issaka Yougbare; Guangheng Zhu; Pingguo Chen; Heyu Ni
Journal:  Adv Hematol       Date:  2012-09-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.